---
title: >-
  The Pervasive Impact of Pruritus on Quality of Life in Patients with Primary
  Biliary Cholangitis (PBC): Real World Experience in TARGET-PBC (APASL)
description: >-
  Explore this publication on real-world evidence: The Pervasive Impact of
  Pruritus on Quality of Life in Patients with Primary Biliary Cholangitis
  (PBC): Real…
date: '2022-01-01'
author: Andrea R. Mospan
category: Publications
tags:
  - APASL
  - 'Yes'
  - Approval & Commercialization
  - PBC
  - Hepatology
  - Care
  - Oral Presentation
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/apasl/the-pervasive-impact-of-pruritus-on-quality-of-life-in/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: the-pervasive-impact-of-pruritus-on-quality-of-life-in
id: 36JoR4TR0vyt2eQHXvPFxT
contentType: article
---

## Challenge

PBC patients report severe pruritus as a primary driver of quality of life impairment, but the multi-domain nature of this burden—across fatigue, cognitive, social, emotional, and other symptom dimensions assessed with validated instruments—had not been quantified in a prospective real-world US cohort.

## Solution

The TARGET-PBC cohort was analyzed using PBC-40, 5D-Itch, and PROMIS Fatigue instruments to compare domain-level quality of life scores across no-itch, mild-itch, and clinically significant itch patient groups, with covariates adjusted in multivariable analysis.

## Impact

Demonstrating that clinically significant PBC pruritus is associated with pervasive, multi-domain quality of life impairment—particularly cognitive and social—provides the clinical meaningfulness evidence for anti-pruritic endpoints and supports regulatory arguments for PRO-based benefit demonstration in PBC trials.

## Use Cases / Links

PRO-based clinical meaningfulness evidence for PBC pruritus endpoints, Multi-domain quality of life burden characterization in PBC for regulatory strategy, Patient burden data supporting anti-pruritic drug development and label claims